CAS: 339186-68-4 - Matuzumab
Fórmula:Unspecified
- Sinónimos:
- Emd 62000
- Emd 7200
- Emd 72000
- Immunoglobulin G1, anti-(human epidermal growth factor receptor) (human-mouse monoclonal 425 γ1-chain), disulfide with human-mouse monoclonal 425 κ-chain, dimer
- Immunoglobulin G1, anti-(human epidermal growth factor receptor) (humanized MAb 425 γ1-chain), disulfide with humanized MAb 425 κ-chain, dimer
- Immunoglobulin G1, anti-(human epidermal growth factor receptor)(humanized MAb 425 gamma-1 chain), disulfide with humanized MAb 425 kappa-chain, dimer
- KGaA
- Matuzumab [INN]
- Merck KGaA
| Marca | Dados do produto | Pureza | Gama de preços | Estimativa de entrega |
|---|---|---|---|---|
 | Matuzumab REF: TM-T9922CAS: 339186-68-4 | 98% | 541,00 € | Sex 19 Jul 24 |
 | Matuzumab - 10 mg/ml REF: 3D-BM165590CAS: 339186-68-4 | Min. 95 Area-% | 1.134,00 €~1.742,00 € | Seg 29 Jul 24 |
Matuzumab
CAS:339186-68-4
Matuzumab: a humanized monoclonal antibody targeting EGFR to inhibit cancer growth.
Pureza:
98%
Cor e Forma:
Solid
Peso molecular:
N/A
Ref: TM-T9922
| 5mg | 541,00 € |
Entrega estimada em Estados Unidos, Sexta-feira 19 de Julho de 2024
Matuzumab - 10 mg/ml
CAS:339186-68-4
Intereferes with EGFR homodimerisation; cancer therapy
Pureza:
Min. 95 Area-%
Cor e Forma:
Powder
Ref: 3D-BM165590
| 1mg | 1.134,00 € | ||
| 2mg | 1.395,00 € | ||
| 5mg | 1.742,00 € |
Entrega estimada em Estados Unidos, Segunda-feira 29 de Julho de 2024
